AbstractIn the course of clinical trials on a birth control vaccine, it was found that some of the immunized women responded poorly to booster immunizations. This vaccine consists of a dimer of the β chain of human chorionic gonadotropin (βhCG) and the α chain of ovine luteinizing hormone (αoLH), linked to tetanus toxoid (TT) as a carrier. Changing this carrier to diphtheria toxoid resulted in reversion to high anti‐hCG antibody titers, indicating the extent to which the carrier influences anti‐ligand responses in this system. The suppression of anti‐hCG responses after booster immunizations was reminiscent of the phenomenon of carrier‐induced, epitope‐specific regulation. In a mouse model designed to test the effects of preimmunization with TT on anti‐hCG responses, we found that a single preimmunization with TT causes reduced anti‐hCG antibody responses in two out of four mouse strains, while anti‐αoLH antibody responses were not affected by the preimmunization with TT. This is particularly interesting considering that βhCG and αoLH were not presented when linked separately to TT. In an effort to devise a strategy to circumvent this carrier‐induced, ligand‐specific hyporesponsiveness, we investigated the effectiveness of a synthetic T helper epitope from TT as carrier. We show that preimmunization with TT causes a less profound reduction in anti‐hCG titers if the preimmunized mice are subsequently injected with αoLH‐βhCG conjugated to a synthetic tetanus toxin peptide recognized by TT‐i
展开▼